Valeant Pharmaceuticals International (VRX) Upgraded at Mizuho

Mizuho upgraded shares of Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) from a neutral rating to a buy rating in a research note published on Tuesday, MarketBeat Ratings reports.

VRX has been the subject of a number of other reports. JPMorgan Chase set a $13.00 price objective on Valeant Pharmaceuticals International and gave the company a sell rating in a report on Wednesday, May 9th. TD Securities cut their price objective on Valeant Pharmaceuticals International from $27.00 to $23.00 and set a buy rating for the company in a report on Thursday, March 1st. Wells Fargo reissued a sell rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, February 28th. Cantor Fitzgerald set a $25.00 price objective on Valeant Pharmaceuticals International and gave the company a buy rating in a report on Wednesday, February 28th. Finally, Deutsche Bank set a $20.00 price objective on Valeant Pharmaceuticals International and gave the company a buy rating in a report on Wednesday, March 21st. Five investment analysts have rated the stock with a sell rating, eleven have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Hold and a consensus price target of $19.30.

Shares of Valeant Pharmaceuticals International opened at $22.03 on Tuesday, Marketbeat.com reports. The firm has a market capitalization of $7.71 billion, a PE ratio of 5.75, a P/E/G ratio of 0.44 and a beta of -0.35. Valeant Pharmaceuticals International has a 1 year low of $21.67 and a 1 year high of $22.26. The company has a debt-to-equity ratio of 5.59, a quick ratio of 0.92 and a current ratio of 1.18.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.60 by $0.29. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Valeant Pharmaceuticals International had a positive return on equity of 27.87% and a negative net margin of 10.65%. Valeant Pharmaceuticals International’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period last year, the business earned $1.79 earnings per share. sell-side analysts anticipate that Valeant Pharmaceuticals International will post 3.25 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were acquired at an average price of $21.83 per share, for a total transaction of $327,450.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Paulson acquired 7,066,629 shares of the business’s stock in a transaction dated Tuesday, March 6th. The shares were acquired at an average price of $15.40 per share, for a total transaction of $108,826,086.60. The disclosure for this purchase can be found here. Insiders have bought a total of 7,136,629 shares of company stock valued at $110,029,937 over the last 90 days. Corporate insiders own 5.87% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its holdings in shares of Valeant Pharmaceuticals International by 122.8% during the 4th quarter. Renaissance Technologies LLC now owns 10,651,189 shares of the specialty pharmaceutical company’s stock valued at $221,332,000 after purchasing an additional 5,870,689 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Valeant Pharmaceuticals International by 9.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,696,348 shares of the specialty pharmaceutical company’s stock valued at $90,686,000 after acquiring an additional 502,273 shares in the last quarter. Two Sigma Investments LP bought a new stake in Valeant Pharmaceuticals International in the 4th quarter valued at approximately $57,221,000. Fosun International Ltd bought a new stake in Valeant Pharmaceuticals International in the 1st quarter valued at approximately $27,705,000. Finally, Chou Associates Management Inc. lifted its stake in Valeant Pharmaceuticals International by 1,006.8% in the 1st quarter. Chou Associates Management Inc. now owns 1,648,992 shares of the specialty pharmaceutical company’s stock valued at $26,252,000 after acquiring an additional 1,500,000 shares in the last quarter. Institutional investors and hedge funds own 50.27% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply